

## Exploring *in vitro* biological cellular responses of Pegylated $\beta$ -cyclodextrins

Juliana Rincón-López<sup>1</sup>, Miguelina Martínez-Aguilera<sup>1</sup>, Patricia Guadarrama<sup>1</sup>, Karla Juárez-Moreno<sup>2,\*</sup>, Yareli Rojas-Aguirre<sup>1,\*</sup>

<sup>1</sup> Laboratorio de Materiales Supramoleculares (SupraMatLab), Instituto de Investigaciones en Materiales, Universidad Nacional Autónoma de México, Circuito Exterior S/N, Ciudad Universitaria, 04510, Mexico City

<sup>2</sup> Centro de Física Aplicada y Tecnología Avanzada, Universidad Nacional Autónoma de México, (CFATA-UNAM), Blvd. Juriquilla #3001 Col. Jurica La Mesa CP 76230, Querétaro, Qto., Mexico

\*Correspondence: [yareli.rojas@materiales.unam.mx](mailto:yareli.rojas@materiales.unam.mx) (Y.R-A), [kjuarez@fata.unam.mx](mailto:kjuarez@fata.unam.mx) (K. J-M)

**Table S1.** Effect of  $\beta$ CDPEGs,  $\beta$ CD, and PEGs on the cell cycle of MC3T3-E1 osteoblasts. Results are presented as mean values  $\pm$  SD of triplicate experiments.

Compound	Parameter	Relative cell population (%)					
		control	25 $\mu$ g/mL	50 $\mu$ g/mL	100 $\mu$ g/mL	250 $\mu$ g/mL	500 $\mu$ g/mL
<i><math>\beta</math>CDPEG2</i>	Sub G0/G1	3.7 $\pm$ 0.1	3.7 $\pm$ 0.4	3.7 $\pm$ 0.2	3.8 $\pm$ 0.4	3.4 $\pm$ 0.3	3.8 $\pm$ 0.3
	G0/G1	47.4 $\pm$ 2.1	47.1 $\pm$ 2.3	44.9 $\pm$ 4.2	47.4 $\pm$ 2.2	47.1 $\pm$ 2.6	43.8 $\pm$ 2.2
	S	18.4 $\pm$ 0.6	16.5 $\pm$ 4.0	15.5 $\pm$ 3.8	15.9 $\pm$ 0.8	18.0 $\pm$ 5.7	23.6 $\pm$ 3.7
	G2/M	36.1 $\pm$ 2.3	36.4 $\pm$ 1.4	34.0 $\pm$ 3.5	37.4 $\pm$ 0.8	30.6 $\pm$ 1.6	27.9 $\pm$ 1.3
	*Viability	100.0 $\pm$ 9.1	97.3 $\pm$ 3.9	100.0 $\pm$ 1.2	76.4 $\pm$ 14.2	85.7 $\pm$ 4.0	77.5 $\pm$ 9.5
<i><math>\beta</math>CDPEG5</i>	Sub G0/G1	3.7 $\pm$ 0.1	3.6 $\pm$ 1.5	4.2 $\pm$ 0.4	3.7 $\pm$ 0.7	4.2 $\pm$ 1.4	4.0 $\pm$ 0.2
	G0/G1	47.4 $\pm$ 2.1	45.5 $\pm$ 2.9	54.7 $\pm$ 4.9	56.5 $\pm$ 2.4	57.7 $\pm$ 1.8	56.4 $\pm$ 1.6
	S	18.6 $\pm$ 0.8	19.8 $\pm$ 1.9	22.5 $\pm$ 1.2	28.1 $\pm$ 1.3	26.5 $\pm$ 2.8	27.0 $\pm$ 2.6
	G2/M	36.1 $\pm$ 2.3	28.2 $\pm$ 0.8	18.6 $\pm$ 0.8	17.2 $\pm$ 5.4	16.6 $\pm$ 4.0	12.0 $\pm$ 1.2
	Viability	100.0 $\pm$ 9.1	77.4 $\pm$ 14.9	59.5 $\pm$ 15.2	51.1 $\pm$ 14.4	55.3 $\pm$ 14.4	53.9 $\pm$ 10.4
<i>PEG2</i>	Sub G0/G1	3.7 $\pm$ 0.1	2.8 $\pm$ 0.4	3.7 $\pm$ 0.3	4.1 $\pm$ 0.1	3.4 $\pm$ 0.5	3.9 $\pm$ 0.2
	G0/G1	47.4 $\pm$ 2.1	46.4 $\pm$ 3.4	5.2 $\pm$ 1.0	50.2 $\pm$ 1.5	49.7 $\pm$ 3.5	47.7 $\pm$ 6.9
	S	18.6 $\pm$ 0.8	23.5 $\pm$ 3.0	25.5 $\pm$ 3.0	26.9 $\pm$ 2.4	24.0 $\pm$ 3.3	24.0 $\pm$ 1.8
	G2/M	36.1 $\pm$ 2.3	11.6 $\pm$ 0.8	13.5 $\pm$ 1.1	12.9 $\pm$ 1.1	13.1 $\pm$ 1.5	12.5 $\pm$ 2.1
	*Viability	100.0 $\pm$ 9.1	68.3 $\pm$ 9.3	55.3 $\pm$ 5.1	52.8 $\pm$ 5.6	49.8 $\pm$ 1.2	53.4 $\pm$ 2.5
<i>PEG5</i>	Sub G0/G1	3.7 $\pm$ 0.1	3.9 $\pm$ 0.4	3.8 $\pm$ 0.6	3.4 $\pm$ 1.2	3.9 $\pm$ 0.6	4.1 $\pm$ 0.5
	G0/G1	47.4 $\pm$ 2.1	46.8 $\pm$ 3.4	50.5 $\pm$ 1.4	54.9 $\pm$ 4.0	52.4 $\pm$ 2.7	53.7 $\pm$ 3.2
	S	18.6 $\pm$ 0.8	21.1 $\pm$ 0.8	23.4 $\pm$ 3.2	22.8 $\pm$ 5.3	23.3 $\pm$ 3.7	24.9 $\pm$ 4.0
	G2/M	36.1 $\pm$ 2.3	18.2 $\pm$ 5.5	17.2 $\pm$ 5.2	10.4 $\pm$ 0.8	13.7 $\pm$ 2.3	13.7 $\pm$ 5.3

	*Viability	100.0±9.1	54.6±10.8	41.9±12.5	46.1±12.8	49.4±9.2	50.6±4.2
<i>βCD</i>	Sub G0/G1	3.7±0.1	3.9±0.1	4.0±0.1	5.5±2.1	5.2±3.2	5.9±1.6
	G0/G1	47.4±2.1	53.8±2.2	53.9±10.3	60.6±2.5	59.5±7.2	59.9±9.2
	S	18.6±0.8	21.6±8.3	24.3±3.8	24.6±3.8	21.8±2.9	18.9±5.7
	G2/M	36.1±2.3	7.8±4.0	7.8±2.4	8.8±4.8	6.4±3.5	6.3±3.5
	*Viability	100.0±9.1	77.3±10.4	54.0±3.7	59.2±8.0	37.0±28.2	70.3±4.2

\*% Cell viability values obtained from the assay reported in Section 2.2.1. have been included to facilitate their comparison with the % relative cell population.

**Table S2.** Effect of  $\beta$ CDPEGs,  $\beta$ CD, and PEGs on the cell cycle of MDCK cells. Results are presented as mean values  $\pm$  SD of triplicate experiments.

Compound	Parameter	Relative cell population (%)					
		control	25 $\mu$ g/mL	50 $\mu$ g/mL	100 $\mu$ g/mL	250 $\mu$ g/mL	500 $\mu$ g/mL
$\beta$ CDPEG2	Sub G0/G1	4.1±0.5	3.7±0.3	3.6±0.5	3.6±1.0	3.7±0.1	3.8±0.3
	G0/G1	44.6±6.4	39.6±1.0	39.5±5.6	38.4±0.7	36.5±2.2	40.9±2.3
	S	13.0±5.4	11.9±4.3	10.7±1.1	10.9±1.7	7.2±3.3	7.4±2.5
	G2/M	31.7±0.2	28.9±1.8	30.8±1.8	27.7±1.0	29.1±5.2	30.5±3.2
	*Viability	100.0±13.0	100.0±11.7	100.0±7.2	94.8±8.1	100.0±2.5	100.0±7.7
$\beta$ CDPEG5	Sub G0/G1	4.1±0.5	3.6±1.5	4.2±0.4	3.7±0.7	4.2±1.4	4.0±0.2
	G0/G1	44.6±6.4	43.1±2.5	42.8±2.8	45.8±5.9	46.5±2.2	50.2±8.0
	S	13.0±5.4	24.5±3.4	27.8±4.3	27.9±0.9	31.1±1.0	30.2±2.7
	G2/M	31.7±0.2	11.9±4.3	10.7±1.1	10.9±1.7	7.2±3.3	7.4±2.5
	*Viability	100.0±13.0	91.8±8.8	83.9±1.9	82.9±4.5	70.8±5.7	72.1±2.2
PEG2	Sub G0/G1	4.1±0.5	3.5±1.0	4.0±0.9	5.5±1.2	4.6±0.3	4.2±0.1
	G0/G1	44.6±6.4	43.6±4.1	45.2±5.5	46.8±1.1	45.0±1.9	45.3±4.3
	S	13.0±5.4	32.4±3.3	29.1±2.2	28.1±5.3	27.5±3.4	29.1±4.2
	G2/M	31.7±0.2	11.6±0.8	13.5±1.1	11.2±0.8	11.6±1.1	9.7±1.0
	*Viability	100.0±13.0	78.9±3.5	69.2±6.8	64.3±2.3	58.6±20.3	74.0±3.9
PEG5	Sub G0/G1	4.1±0.5	3.3±0.4	3.5±0.3	3.6±0.5	3.3±0.2	3.5±0.6
	G0/G1	44.6±6.4	45.4±3.1	47.9±10.4	56.3±1.2	47.3±7.4	46.4±7.6
	S	13.0±5.4	26.0±3.4	28.9±1.4	25.0±0.9	26.8±2.9	25.4±2.8
	G2/M	31.7±0.2	13.1±2.3	11.5±1.7	11.7±0.6	11.6±1.1	16.7±3.4

	*Viability	100.0±13.0	79.5±5.4	76.9±2.5	71.8±7.1	71.1±10.7	81.4±5.6
	Sub G0/G1	4.1±0.5	2.8±0.9	3.7±0.3	4.9±1.1	4.1±1.1	3.5±0.7
	G0/G1	44.6±6.4	42.0±8.9	36.0±7.4	41.8±3.7	41.8±3.2	45.1±5.0
βCD	S	13.0±5.4	13.3±2.2	38.6±2.4	35.2±1.2	35.6±3.1	37.8±4.0
	G2/M	31.7±0.2	37.8±12.4	17.1±4.1	9.4±1.3	2.7±0.5	7.2±2.6
	*Viability	100.0±13.0	95.1±5.8	97.6±9.4	73.7±6.4	79.0±2.7	76.1±2.8

\*% Cell viability values obtained from the assay reported in Section 2.3.1. have been included to facilitate their comparison with the % relative cell population.